GW Pharmaceuticals PLC- ADR (GWPH) was Resumed by Leerink Partners to “Outperform” and the brokerage firm has set the Price Target at $162. Leerink Partners advised their investors in a research report released on Oct 4, 2016.
Many Wall Street Analysts have commented on GW Pharmaceuticals PLC- ADR. Company shares were Reiterated by Cantor Fitzgerald on Sep 26, 2016 to “Buy”, Firm has raised the Price Target to $ 182 from a previous price target of $165 .GW Pharmaceuticals PLC- ADR was Upgraded by Numis to ” Hold” on Aug 26, 2016. Shares were Reiterated by Cantor Fitzgerald on Aug 9, 2016 to “Buy” and Lowered the Price Target to $ 165 from a previous price target of $181 .
On the company’s financial health, GW Pharmaceuticals PLC- ADR reported $-0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.10. The company had revenue of $2.30 million for the quarter, compared to analysts expectations of $2.76 million. The company’s revenue was down -73.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.085 EPS.
GW Pharmaceuticals PLC- ADR opened for trading at $131.54 and hit $135.16 on the upside on Friday, eventually ending the session at $132.73, with a gain of 2.12% or 2.76 points. The heightened volatility saw the trading volume jump to 8,45,719 shares. Company has a market cap of $2,889 M.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Companys product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.